http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16932871

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
endingPage 254
issn 2374-2437
issueIdentifier 2
pageRange 248-254
publicationName JAMA Oncology
startingPage 248
bibliographicCitation Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung TH, Kessler Z, Woods C, Kim B, Miller BW, Wernecke M, Kim C, McKean S, Gelperin K, MaCurdy TE, Kelman JA, Graham DJ. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries. JAMA Oncol. 2020 Feb 01;6(2):248–54. PMID: 31855259; PMCID: PMC6990831.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e2b7a421c5cfa133e43f0cdfbb8ee99
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3aa3f1fd4193a6c08b90680031665e93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dcaa04be4b97284e577d8d4b6cf048ae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a775037a001eb915329a7a9625095e0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e8d2bb0a9c548f2874eb26cf86b56a5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_383751355df10ba86f0dd950e0ac156b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ed80d20c9b27bfdeacefb0b21262f6d4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e65ef45b4d88d85a3830b779f789c3f0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2e2244512dc876c5ad51d7f08361ded4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6eb2755279b6c5307966cb94bb3ae040
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0adfdd2513a4e9aaf079bc4f134b2aa1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d475ef6ebabb9391dd4f61f8aa822e5b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0df4e927baa5b6adcf9b04465cf26727
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_21babcdfbfec9731dc21e5ff0c5e62bc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6000ceaaa50c238b9228264acaf7608e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88cebc5b64fa2eeeb09ce71177103538
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0108e72e299535bd17f5c2cad2ce2684
date 2020-02-01^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/31855259
https://pubmed.ncbi.nlm.nih.gov/PMC6990831
https://doi.org/10.1001/jamaoncol.2019.3994
isPartOf https://portal.issn.org/resource/ISSN/2374-2437
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43608
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries
discusses http://id.nlm.nih.gov/mesh/M0592589
http://id.nlm.nih.gov/mesh/M0490629
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0018169
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D006278
http://id.nlm.nih.gov/mesh/D008224Q000188
http://id.nlm.nih.gov/mesh/D052999Q000008
http://id.nlm.nih.gov/mesh/D015451Q000188
http://id.nlm.nih.gov/mesh/D007342
http://id.nlm.nih.gov/mesh/D011687Q000008
http://id.nlm.nih.gov/mesh/D000970Q000008
hasSubjectTerm http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D008224Q000401
http://id.nlm.nih.gov/mesh/D015897
http://id.nlm.nih.gov/mesh/D015451Q000401
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D014481
http://id.nlm.nih.gov/mesh/D012008
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D007239Q000188
http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D007239Q000401
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D004311
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11625818
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8389
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8917

Showing number of triples: 1 to 65 of 65.